Steven Green, MD
Internal Medicine · Buffalo, NYNPI 1053792374
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $20,623 of the $26,476 with a category attached, or 77.9%. 13 manufacturers reported payments, led by GSK at 39.8% of the total. 2025 is the largest year on record at $12,264, more than ten times the $108 reported in 2019. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 34 payments — averaging $778.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$11K
- Incyte Corporation$9K
- Jazz Pharmaceuticals Inc.$3K
- CTI Biopharma Corp.$3K
- Pharmaessentia USA Corporation$201
- Daiichi Sankyo Inc.$125
- plus $778 from 7 others
Across 34 payments — averaging $1951.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$64K
- Sumitomo Pharma America, Inc.$2K
- Stemline Therapeutics Inc.$225
What the payments were for
- Consulting fees$20,62378%
- Travel & lodging$3,89115%
- Food & beverage$1,7847%
- Education$1781%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 6 | $10,541 |
| Incyte Corporation | 9 | $8,764 |
| Jazz Pharmaceuticals Inc. | 1 | $3,348 |
| CTI Biopharma Corp. | 7 | $2,719 |
| Pharmaessentia USA Corporation | 3 | $201 |
| Daiichi Sankyo Inc. | 1 | $125 |
| Gilead | 1 | $125 |
| Bristol Myers Squibb | 1 | $125 |
| Sanofi US Services Inc. | 1 | $125 |
| AstraZeneca | 1 | $111 |
| Agios Pharmaceuticals, Inc. | 1 | $108 |
| Adaptive Biotechnologies Corporation | 1 | $105 |
| Astellas Pharma US Inc | 1 | $79 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,476 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxyurea | 24 | $284 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Buffalo
- Nicholas RobinsonBuffalo$2.9M
- Anthony MartinezBuffalo$1.6M
- Sanjay SethiBuffalo$733K
- Rosalind SulaimanBuffalo$145K
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Javier MoralesGreenvale$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.